Literature DB >> 34628504

ECCO-ESGAR Topical Review on Optimizing Reporting for Cross-Sectional Imaging in Inflammatory Bowel Disease.

Torsten Kucharzik1, Jeroen Tielbeek2, Dan Carter3, Stuart A Taylor4, Damian Tolan5, Rune Wilkens6, Robert V Bryant7, Christine Hoeffel8, Isabelle De Kock9, Christian Maaser10, Giovanni Maconi11, Kerri Novak12, Søren R Rafaelsen13, Martina Scharitzer14, Antonino Spinelli15,16, Jordi Rimola17.   

Abstract

BACKGROUND AND AIMS: The diagnosis and follow up of patients with inflammatory bowel disease [IBD] requires cross-sectional imaging modalities, such as intestinal ultrasound [IUS], magnetic resonance imaging [MRI] and computed tomography [CT]. The quality and homogeneity of medical reporting are crucial to ensure effective communication between specialists and to improve patient care. The current topical review addresses optimized reporting requirements for cross-sectional imaging in IBD.
METHODS: An expert consensus panel consisting of gastroenterologists, radiologists and surgeons convened by the ECCO in collaboration with ESGAR performed a systematic literature review covering the reporting aspects of MRI, CT, IUS, endoanal ultrasonography and transperineal ultrasonography in IBD. Practice position statements were developed utilizing a Delphi methodology incorporating two consecutive rounds. Current practice positions were set when ≥80% of the participants agreed on a recommendation.
RESULTS: Twenty-five practice positions were developed, establishing standard terminology for optimal reporting in cross-sectional imaging. Assessment of inflammation, complications and imaging of perianal CD are outlined. The minimum requirements of a standardized report, including a list of essential reporting items, have been defined.
CONCLUSIONS: This topical review offers practice recommendations to optimize and homogenize reporting in cross-sectional imaging in IBD.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Inflammatory bowel disease [IBD]; cross-sectional imaging; endoanal ultrasonography [EAUS]; intestinal ultrasound [IUS]; magnetic resonance imaging [MRI]; reporting; transperineal ultrasonography [PUS

Mesh:

Year:  2022        PMID: 34628504     DOI: 10.1093/ecco-jcc/jjab180

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  4 in total

1.  Imaging in inflammatory bowel disease: current and future perspectives.

Authors:  Nader Shaban; Caroline L Hoad; Iyad Naim; Meshari Alshammari; Shellie Jean Radford; Christopher Clarke; Luca Marciani; Gordon Moran
Journal:  Frontline Gastroenterol       Date:  2022-06-02

2.  The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases-an international Delphi consensus survey.

Authors:  Gorm Roager Madsen; Rune Wilkens; Trine Boysen; Johan Burisch; Robert Bryant; Dan Carter; Krisztina Gecse; Christian Maaser; Giovanni Maconi; Kerri Novak; Carolina Palmela; Leizl Joy Nayahangan; Martin Grønnebaek Tolsgaard
Journal:  Aliment Pharmacol Ther       Date:  2022-04-29       Impact factor: 9.524

Review 3.  Role of Multiparametric Intestinal Ultrasound in the Evaluation of Response to Biologic Therapy in Adults with Crohn's Disease.

Authors:  Pierluigi Puca; Livio Enrico Del Vecchio; Maria Elena Ainora; Antonio Gasbarrini; Franco Scaldaferri; Maria Assunta Zocco
Journal:  Diagnostics (Basel)       Date:  2022-08-17

4.  METRIC-EF: magnetic resonance enterography to predict disabling disease in newly diagnosed Crohn's disease-protocol for a multicentre, non-randomised, single-arm, prospective study.

Authors:  Shankar Kumar; Andrew Plumb; Sue Mallett; Gauraang Bhatnagar; Stuart Bloom; Caroline S Clarke; John Hamlin; Ailsa L Hart; Ilan Jacobs; Simon Travis; Roser Vega; Steve Halligan; Stuart Andrew Taylor
Journal:  BMJ Open       Date:  2022-10-03       Impact factor: 3.006

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.